Effect of aβ2-GPI Antibodies From Patient No. 1 on PT of Normal Plasma (NP) and Plasma From Patients on Oral Anticoagulants (OA), Measured Using Different Thromboplastin Preparations (INR of pooled anticoagulated plasma = 2.7)
| Thromboplastin Preparation . | PT s (+buffer) . | PT s (+normal IgG) . | PT s (+IgG anti–β2-GPI) . | |||
|---|---|---|---|---|---|---|
| NP . | OA . | NP . | OA . | NP . | OA . | |
| Innovin | 12.7 | 36.9 | 12.9 | 37.3 | 11.5 (−1.4) | 31.7 (−5.6) |
| Thromborel S | 17.9 | 38.5 | 17.9 | 39.9 | 14.5 (−3.4) | 30.1 (−9.8) |
| Thromboplastin IS | 17.8 | 53.6 | 17.4 | 56.8 | 15.2 (−2.2) | 37.5 (−19.3) |
| IL-HS | 18.1 | 33.7 | 18.0 | 34.6 | 16.6 (−1.4) | 28.9 (−5.7) |
| Thromboplastin Preparation . | PT s (+buffer) . | PT s (+normal IgG) . | PT s (+IgG anti–β2-GPI) . | |||
|---|---|---|---|---|---|---|
| NP . | OA . | NP . | OA . | NP . | OA . | |
| Innovin | 12.7 | 36.9 | 12.9 | 37.3 | 11.5 (−1.4) | 31.7 (−5.6) |
| Thromborel S | 17.9 | 38.5 | 17.9 | 39.9 | 14.5 (−3.4) | 30.1 (−9.8) |
| Thromboplastin IS | 17.8 | 53.6 | 17.4 | 56.8 | 15.2 (−2.2) | 37.5 (−19.3) |
| IL-HS | 18.1 | 33.7 | 18.0 | 34.6 | 16.6 (−1.4) | 28.9 (−5.7) |